A Phase I Study of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma

Full Title

Phase 1 Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma (PBTC-047)

Purpose

Panobinostat is a drug used to treat a cancer of the bone marrow in adults called multiple myeloma. Laboratory studies suggest that this drug may also kill diffuse intrinsic pontine glioma cells (a type of brain tumor typically diagnosed in children).

In this study, researchers want to find the optimal dose of panobinostat to give to children with diffuse intrinsic pontine glioma and to observe its anticancer effects. Panobinostat is a capsule that is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have diffuse intrinsic pontine glioma that continues to grow despite prior radiation therapy.
  • Patients must recover from the serious side effects of prior treatments before entering the study.
  • This study is for children who are at least 2 years of age and no older than 21 years.

For more information about this study and to inquire about eligibility, please contact Dr. Kim Kramer at 212-639-3751.

Protocol

16-872

Phase

I

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators

Locations